Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.

Recently, the General Office of the State Council communicated Measures of Ministry of Commerce and the Ministry of Science and technology (MOST) for Further Encouraging Foreign Investment in Establishing Research and Development (R&D) Centers in China.

Labcorp, a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.

Qiagen said Monday that its QIAstat-Dx syndromic testing system is expected to be available soon in Japan with a SARS-CoV-2 Respiratory Panel that can detect more than 20 pathogens from a patient sample.

Blood gas diagnosis mainly involves measuring the pH value, pCO2, pO2, and other gases dissolved in human blood to understand the body's respiratory function and acid-base balance status.

China's foreign ministry said on Tuesday that all inbound travellers will only need to show COVID-19 antigen tests result taken within 48 hours before boarding flights starting April 29, dropping the PCR test requirement.

Curative Inc., a leading health services company that recently launched a new health plan out of Texas, announces the spin-off of Sensible Diagnostics, whose aim is to commercialize their groundbreaking point-of-care PCR testing platform.

Stockholm, Sweden-based Devyser Diagnostics on Monday announced that it has inked a collaboration and distribution agreement that gives Thermo Fisher Scientific the exclusive rights to commercialize its post-transplant portfolio of next-generation sequencing (NGS) products in North America and Europe.

On April 18, Sino Biological Inc., a protein and antibody R&D and production expert, signed a strategic cooperation agreement with Megarobo.

A large population-based cohort study has linked COVID-19 to increased risk of diabetes, adding to the evidence that SARS-CoV-2 infection may contribute to the development of the metabolic disorder.